<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208285</url>
  </required_header>
  <id_info>
    <org_study_id>VX10-770-013</org_study_id>
    <nct_id>NCT01208285</nct_id>
  </id_info>
  <brief_title>Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects</brief_title>
  <official_title>A Phase 1 Non-Randomized, Open-Label Study to Assess the Safety and Pharmacokinetics of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetics and safety of a single dose
      of VX-770 in subjects with moderate hepatic impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VX-770 pharmacokinetic parameters</measure>
    <time_frame>4 or 10 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VX-770 metabolites pharmacokinetic parameters</measure>
    <time_frame>4 or 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by adverse events, clinical laboratory values, standard electrocardiograms (ECGs), and vital signs</measure>
    <time_frame>up to 40 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>In Development for Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>approximately 12 male and female subjects with moderate hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>approximately 12 healthy male and female subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-770</intervention_name>
    <description>150 mg oral tablet</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group A (Subjects with Hepatic Impairment):

          -  male or female between 18 and 65 years of age

          -  subjects must have a Child-Pugh total score of 7 to 9

          -  subjects must agree to use 1 highly effective method of contraception during the study
             and for 90 days after the completion of the study

          -  subjects must have a body mass index (BMI) of 18 to 35 kg/m2

        Group B (Healthy Subjects):

          -  male or female between 18 and 65 years of age

          -  subjects will match subjects with hepatic impairment for sex, BMI, cigarette smoking
             habit, and age

          -  subjects must agree to use 1 highly effective method of contraception during the study
             and for 90 days after the completion of the study

        Exclusion Criteria:

        Group A (Subjects with Hepatic Impairment):

          -  subjects who are not clinically stable or who have a history of any illness that, in
             the opinion of the investigator or the subject's general practitioner, might confound
             the results of the study or pose an additional risk in administering study drug(s) to
             the subject

          -  subjects who are unwilling or unable to discontinue use of any inhibitors or inducers
             of CYP3A

          -  subjects who have a history of alcohol abuse within 1 year or illicit drug abuse
             within 2 years

          -  subjects who smoke more than 10 cigarettes per day

          -  subjects who have fluctuating or rapidly deteriorating hepatic function

          -  subjects who have significant renal dysfunction

          -  subjects who have HIV, or active hepatitis B

          -  subjects who have previous solid organ or bone marrow transplantation

        Group B (Healthy Subjects):

          -  subjects who have a history of any illness that, in the opinion of the investigator or
             the subject's general practitioner, might confound the results of the study or pose an
             additional risk in administering study drug(s) to the subject

          -  subjects who are unwilling or unable to discontinue use of any inhibitors or inducers
             of CYP3A

          -  subjects who have a history of alcohol or illicit drug abuse within 2 years

          -  subjects who smoke more than 10 cigarettes per day

          -  subjects who have HIV, hepatitis C, or active hepatitis B
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Hradec Králové</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2010</study_first_submitted>
  <study_first_submitted_qc>September 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2010</study_first_posted>
  <last_update_submitted>January 11, 2011</last_update_submitted>
  <last_update_submitted_qc>January 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Monitor</name_title>
    <organization>Vertex Pharmaceuticals Incorporated</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

